ArticleDrug safety2013

Risk factors for adverse symptoms during dipeptidyl peptidase-IV inhibitor therapy: a questionnaire-based study carried out by the Japan Pharmaceutical Association Drug Event Monitoring project in Kumamoto Prefecture.

Ayami Kajiwara et al.PubMed ↗Publisher ↗

No numbers read from the abstract.